A Prospective Phase I/II Study: Combination Chemotherapy with Docetaxel and Pemetrexed as Second-Line Treatment in Patients with Stage IIIB/IV Non-Small Cell Lung Cancer

Por Kroeber, Vinzenz, Nagel, Sylke, Schuette, Wolfgang, Blankenburg, Thomas
Publicado em 2014

Second-line Treatment of Stage III/IV Non-Small-Cell Lung Cancer (NSCLC) with pemetrexed in routine clinical practice: Evaluation of performance status and health-related quality o...

Por Schuette Wolfgang, Tesch Hans, Büttner Hartwig, Krause Thomas, Soldatenkova Victoria, Stoffregen Clemens
Publicado em 2012-01-01

Second-line Treatment of Stage III/IV Non-Small-Cell Lung Cancer (NSCLC) with pemetrexed in routine clinical practice: Evaluation of performance status and health-related quality o...

Por Schuette, Wolfgang, Tesch, Hans, Büttner, Hartwig, Krause, Thomas, Soldatenkova, Victoria, Stoffregen, Clemens
Publicado em 2012

Randomized Phase II Study of Palifermin for Reducing Dysphagia in Patients Receiving Concurrent Chemoradiotherapy for Locally Advanced Unresectable Non-small Cell Lung Cancer

Por Schuette, Wolfgang, Krzakowski, Maciej J., Massuti, Bartomeu, Otterson, Gregory A., Lizambri, Richard, Wei, Helen, Berger, Dietmar P., Chen, Yuhchyau
Publicado no J Thorac Oncol (2012)

Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer

Por Manegold, Christian, Vansteenkiste, Johan, Cardenal, Felipe, Schuette, Wolfgang, Woll, Penella J., Ulsperger, Ernst, Kerber, Anne, Eckmayr, Josef, von Pawel, Joachim
Publicado em 2012